DK1944316T3 - Nucleophosminprotein- (npm) mutanter, tilsvarende gensekvenser og anvendelser deraf - Google Patents
Nucleophosminprotein- (npm) mutanter, tilsvarende gensekvenser og anvendelser deraf Download PDFInfo
- Publication number
- DK1944316T3 DK1944316T3 DK07021463.0T DK07021463T DK1944316T3 DK 1944316 T3 DK1944316 T3 DK 1944316T3 DK 07021463 T DK07021463 T DK 07021463T DK 1944316 T3 DK1944316 T3 DK 1944316T3
- Authority
- DK
- Denmark
- Prior art keywords
- npm
- seq
- mutated
- nes
- npmc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Isoleret oligonukleotidsekvens, der koder for en muteret version af humant nucleophosminprotein (NPM) NP_002511 kendetegnet ved at have en cytoplasmisk location, omfatte en mutation, der resulterer i tab af mindst én af tryptophanresterne ved positionerne 288 og 290, omfatte et signalmønster af nuklear eksport (NES) i det C-terminale område og det C-terminale område indbefatter VSLRK (SEQ ID NO 29).
2. Oligonukleotidsekvens ifølge krav 1, hvor i den kodede, muterede version af human NPM NP 002511 begge tryptophanrester 288 og 290 er muterede.
3. Oligonukleotidsekvens ifølge krav 1, hvor i den kodede, muterede version af human NPM NP 002511 kun tryptophanresten 290 er muteret.
4. Oligonukleotidsekvens ifølge krav 1, hvor den kodede, muterede version af human NPM NP 002511 endvidere omfatter en D-aminosyre (asparaginsyre) opstrøms for L-aminosyre (leucin) ved den N-terminale ende af NES-mønstret.
5. Oligonukleotidsekvens ifølge et hvilket som helst af kravene 1 til 3, hvor i den kodede, muterede version af human NPM NP_002511, NES omfatter en aminosyresekvens udvalgt fra gruppen bestående af LCLAVEEVSL (SEQ ID NO 6); LCMAVEEVSL (SEQ ID NO 7); LCVAVEEVSL (SEQ ID NO 8); LSRAVEEVSL (SEQ ID NO 9); LCTAVEEVSL (SEQ ID NO 10); LSQAVEEVSL (SEQ ID NO 11); LCI-IAVEEVSL (SEQ ID NO 12); LCRAVEEVSL (SEQ ID NO 13); LCRGVEEVSL (SEQ ID NO 14); LCQAVEEVSL (SEQ ID NO 15); LCAAVEEVSL (SEQ ID NO 16); LCKAVEEVSL (SEQ ID NO 17); LWQSLAQVSL (SEQ ID NO 18); LWQSLEKVSL (SEQ ID NO 19); LWQSLSKVSL (SEQ ID NO 20); LCTFLEEVSL (SEQ ID NO 21); LWQCFAQVSL (SEQ ID NO 22); LWQCFSKVSL (SEQ ID NO 23); LWQRFQEVSL (SEQ ID NO 24); LWQDFLNRL (SEQ ID NO 25); LWQSMEEVSL (SEQ ID NO 26) eller LWQRMEEVSL (SEQ ID NO 27) og LWQCCSQVSL (SEQ ID NO 28)
6. Oligonukleotidsekvens ifølge et hvilket som helst af kravene 1 til 4, hvor i den kodede, muterede version af human NPM NP_002511 NES omfatter en ami-nosyresekvens udvalgt fra gruppen bestående af: A) DLCLAVEEVSLRK B) DLCMAVEEVSLRK C) DLCVAVEEVSLRK D) DLCLAVEEVSLRK E) DLWQSLAQVSLRK F) DLWQSLEKVSLRK
7. Oligonukleotidsekvens ifølge krav 1, hvor den kodede, muterede version af human NPM NP 002511 endvidere er kendetegnet ved, at den er kondenseret til et reporterprotein, hvor reporterproteinet er udvalgt fra gruppen bestående af EGFP, β-galactosidase, luciferase og GFP.
8. Isoleret oligonukleotid ifølge et hvilket som helst af de foregående krav, hvor oligonukleotidet er et deoxyribonukleotid eller en ribonukleotidsekvens eller komplementære sekvenser dertil.
9. Oligonukleotidsekvens ifølge krav 8, hvor deoxyribonukleotidsekvensen indbefatter mindst én af sekvenserne med følgende GenBank-deponeringsnumre: AY740634, AY740635, AY740636, A740637, AY740638, AY740639.
10. Oligonukleotidsekvens ifølge krav 1, hvor sekvenser er mærket med et middel udvalgt fra gruppen bestående af et fluorescerende stof, biotin, en radioisotop og en nanopartikel.
11. Fremgangsmåde in vitro til diagnosticering af akut myeloid leukæmi og/eller monitorering af residual sygdom ved detektering af NPM-mutationer som defineret i krav 1, hvilken fremgangsmåde anvender et middel udvalgt fra gruppen bestående af oligonukleotidsonder, primere, epitoperog antistoffer.
12. Fremgangsmåde ifølge krav 11, hvor NPM-mutationerne detekteres med mindst én primer og/eller oligonukleotidsonde, der genkender én eller flere af NPM-mutationerne, og hvor primeren eller oligonukleotidsonden er mærket med et middel udvalgt fra gruppen bestående af et fluorescerende stof, biotin, en radioisotop og en nanopartikel.
13. Ekspressionsvektor omfattende en oligonukleotidsekvens som defineret i krav 1.
14. Værtscelle transficeret med en ekspressionsvektor som defineret i krav 13.
15. Fremgangsmåde til anvendelse af værtscellen ifølge krav 14 som studiemodel af NPMc+ AML til screening af nye lægemidler.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000534A ITRM20040534A1 (it) | 2004-10-29 | 2004-10-29 | Mutanti della proteina nucleofosmina (npm), sequenze geniche corrispondenti e relativi usi. |
| EP05813231.7A EP1807448B1 (en) | 2004-10-29 | 2005-10-28 | Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1944316T3 true DK1944316T3 (da) | 2015-07-20 |
Family
ID=36096144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10184598.0T DK2319865T3 (da) | 2004-10-29 | 2005-10-28 | Nucleophosminprotein- (npm) mutanter, der omfatter gensekvenser, og anvendelser deraf |
| DK07021463.0T DK1944316T3 (da) | 2004-10-29 | 2005-10-28 | Nucleophosminprotein- (npm) mutanter, tilsvarende gensekvenser og anvendelser deraf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10184598.0T DK2319865T3 (da) | 2004-10-29 | 2005-10-28 | Nucleophosminprotein- (npm) mutanter, der omfatter gensekvenser, og anvendelser deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US8222370B2 (da) |
| EP (4) | EP1807448B1 (da) |
| CN (1) | CN101160320B (da) |
| CA (1) | CA2585965C (da) |
| CY (1) | CY1116527T1 (da) |
| DK (2) | DK2319865T3 (da) |
| ES (4) | ES2607987T3 (da) |
| HK (2) | HK1121171A1 (da) |
| HU (1) | HUE025263T2 (da) |
| IT (1) | ITRM20040534A1 (da) |
| PL (1) | PL1944316T3 (da) |
| PT (1) | PT1944316E (da) |
| SI (1) | SI1944316T1 (da) |
| WO (1) | WO2006046270A2 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040534A1 (it) | 2004-10-29 | 2005-01-29 | Brunangelo Falini | Mutanti della proteina nucleofosmina (npm), sequenze geniche corrispondenti e relativi usi. |
| KR101660322B1 (ko) * | 2011-04-28 | 2016-09-29 | 아크레이 가부시키가이샤 | ＮＰＭ1 유전자의 ｅｘｏｎ12 변이의 검출용 프로브 및 그 용도 |
| CN102382896A (zh) * | 2011-12-06 | 2012-03-21 | 苏州苏大赛尔免疫生物技术有限公司 | Npm1基因突变检测方法及其试剂盒 |
| WO2017049002A1 (en) * | 2015-09-15 | 2017-03-23 | Massachusetts Institute Of Technology | A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system |
| EP4327819A3 (en) | 2017-06-30 | 2024-05-29 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| WO2019214058A1 (zh) * | 2018-05-11 | 2019-11-14 | 南京先声医学检验有限公司 | 引物、引物组合、试剂盒及其应用 |
| CN114591410B (zh) * | 2022-03-25 | 2022-09-20 | 东北农业大学 | 玉米miRNA的靶基因序列及其编码蛋白在抗植物粗缩病中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5529925A (en) * | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
| US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
| CN1331117A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——nucleophosmin9.68和编码这种多肽的多核苷酸 |
| AU2003257434A1 (en) | 2002-07-09 | 2004-01-23 | Degussa Ag | L-amidase from rhizobium huautlense |
| GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US7314750B2 (en) * | 2002-11-20 | 2008-01-01 | Affymetrix, Inc. | Addressable oligonucleotide array of the rat genome |
| AU2003302986A1 (en) * | 2002-12-13 | 2004-07-09 | Aurelium Biopharma Inc. | Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| US7288529B2 (en) * | 2003-04-24 | 2007-10-30 | New York University | ALK protein tyrosine kinase, cells and methods embodying and using same |
| ITRM20040534A1 (it) | 2004-10-29 | 2005-01-29 | Brunangelo Falini | Mutanti della proteina nucleofosmina (npm), sequenze geniche corrispondenti e relativi usi. |
-
2004
- 2004-10-29 IT IT000534A patent/ITRM20040534A1/it unknown
-
2005
- 2005-10-28 ES ES05813231.7T patent/ES2607987T3/es active Active
- 2005-10-28 EP EP05813231.7A patent/EP1807448B1/en active Active
- 2005-10-28 WO PCT/IT2005/000634 patent/WO2006046270A2/en active Application Filing
- 2005-10-28 DK DK10184598.0T patent/DK2319865T3/da active
- 2005-10-28 ES ES10184598.0T patent/ES2654564T3/es active Active
- 2005-10-28 ES ES17181518T patent/ES2755875T3/es active Active
- 2005-10-28 US US11/666,542 patent/US8222370B2/en active Active
- 2005-10-28 CA CA2585965A patent/CA2585965C/en active Active
- 2005-10-28 HU HUE07021463A patent/HUE025263T2/en unknown
- 2005-10-28 EP EP17181518.6A patent/EP3284750B1/en active Active
- 2005-10-28 DK DK07021463.0T patent/DK1944316T3/da active
- 2005-10-28 EP EP10184598.0A patent/EP2319865B1/en active Active
- 2005-10-28 ES ES07021463.0T patent/ES2542339T3/es active Active
- 2005-10-28 PL PL07021463T patent/PL1944316T3/pl unknown
- 2005-10-28 SI SI200531981T patent/SI1944316T1/sl unknown
- 2005-10-28 EP EP07021463.0A patent/EP1944316B1/en active Active
- 2005-10-28 PT PT70214630T patent/PT1944316E/pt unknown
- 2005-10-28 CN CN200580045036.0A patent/CN101160320B/zh not_active Expired - Fee Related
-
2007
- 2007-11-02 US US11/982,679 patent/US8501924B2/en active Active
-
2009
- 2009-01-14 HK HK09100376.5A patent/HK1121171A1/xx unknown
-
2013
- 2013-08-06 US US13/959,739 patent/US9725767B2/en active Active
-
2015
- 2015-06-25 US US14/750,331 patent/US10155989B2/en active Active
- 2015-07-10 CY CY20151100605T patent/CY1116527T1/el unknown
-
2017
- 2017-12-18 US US15/844,912 patent/US10487366B2/en active Active
-
2018
- 2018-05-28 HK HK18106934.6A patent/HK1247222A1/zh unknown
-
2019
- 2019-10-10 US US16/598,935 patent/US20200032354A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,970 patent/US20230212680A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230212680A1 (en) | Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof | |
| US7153700B1 (en) | Methods and compositions for diagnosing and predicting the behavior of cancer | |
| WO1995013292A9 (en) | Bcl-2-associated proteins | |
| WO2004016317A1 (en) | Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer | |
| FALINI et al. | Sommaire du brevet 2585965 | |
| FALINI et al. | Patent 2585965 Summary | |
| JP2010057497A (ja) | 抗癌剤の開発および癌の診断のための、腫瘍の発生に関与することが同定されたマウスゲノム領域の使用 | |
| WO2002042452A2 (en) | Adapter protein and gene encoding it | |
| US7041783B2 (en) | Survivin-binding proteins, encoding nucleic acids, and methods of use | |
| Cohen et al. | Etk | |
| Chen et al. | Mechanism of Abnormal Cell-Extracellular Matrix Interactions in Human Breast Cancer. |